Skip to main content
. 2024 Feb 6;47(3):310–324. doi: 10.1007/s00270-023-03657-x

Fig. 1.

Fig. 1

Kaplan–Meier plot showing differences in (A) overall survival, (B) progression-free survival and (C) hepatic progression-free survival for 1st line TARE, 1st line TARE + concomitant therapy (CT), 2nd line TARE, and > 2nd line TARE. Levels of significance: p < 0.05 (Log-rank test)